JP2004538275A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538275A5
JP2004538275A5 JP2003511859A JP2003511859A JP2004538275A5 JP 2004538275 A5 JP2004538275 A5 JP 2004538275A5 JP 2003511859 A JP2003511859 A JP 2003511859A JP 2003511859 A JP2003511859 A JP 2003511859A JP 2004538275 A5 JP2004538275 A5 JP 2004538275A5
Authority
JP
Japan
Prior art keywords
composition
ifn
buffer
glycine
achieves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003511859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021464 external-priority patent/WO2003006053A1/en
Publication of JP2004538275A publication Critical patent/JP2004538275A/ja
Publication of JP2004538275A5 publication Critical patent/JP2004538275A5/ja
Pending legal-status Critical Current

Links

JP2003511859A 2001-07-09 2002-07-09 ヒトインターフェロン−β配合物 Pending JP2004538275A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30339501P 2001-07-09 2001-07-09
PCT/US2002/021464 WO2003006053A1 (en) 2001-07-09 2002-07-09 HUMAN INTERFERON-β FORMULATIONS

Publications (2)

Publication Number Publication Date
JP2004538275A JP2004538275A (ja) 2004-12-24
JP2004538275A5 true JP2004538275A5 (enExample) 2006-01-05

Family

ID=23171889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003511859A Pending JP2004538275A (ja) 2001-07-09 2002-07-09 ヒトインターフェロン−β配合物

Country Status (7)

Country Link
US (2) US20030118548A1 (enExample)
JP (1) JP2004538275A (enExample)
AR (1) AR034749A1 (enExample)
PE (1) PE20030303A1 (enExample)
TW (1) TWI241193B (enExample)
UY (1) UY27373A1 (enExample)
WO (1) WO2003006053A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP2007530419A (ja) * 2003-07-11 2007-11-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 改良組換えヒトインターフェロン−β−１ｂポリペプチド
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
AU2005304486B2 (en) * 2004-11-10 2011-08-11 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
AR053284A1 (es) * 2005-05-19 2007-04-25 Schering Ag Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
UY29544A1 (es) * 2005-05-19 2006-12-29 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
AU2006275800A1 (en) * 2005-07-29 2007-02-08 Novartis Ag Method and system for in vitro protein folding

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
DE2943016C2 (de) * 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) * 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
NL7907791A (nl) * 1979-10-23 1981-04-27 Stichting Rega V Z W Werkwijze voor het zuiveren van interferon.
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4643566A (en) * 1984-07-20 1987-02-17 Canon Kabushiki Kaisha Particle analyzing apparatus
DE3628468A1 (de) * 1986-08-21 1988-03-03 Thomae Gmbh Dr K Neue applikationsformen fuer (alpha)-interferone
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2687843A1 (fr) * 1992-02-24 1993-08-27 Motorola Semiconducteurs Transistor bipolaire lateral pnp et procede de fabrication.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP3466765B2 (ja) * 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Similar Documents

Publication Publication Date Title
US7879805B2 (en) High temperature stable peptide formulation
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
CN1130223C (zh) 包含生长激素,氨基酸和非离子去污剂的药物配方
CN1523997B (zh) 稳定的白介素2
ES2303361T3 (es) Conjugados de interferon-alfa-polimero con actividad biologica potenciada y procedimientos de preparacion de los mismos.
TWI409082B (zh) 用於長效型粒細胞集落刺激因子（ｇ－ｃｓｆ）共軛物之液態劑型
SI1687019T1 (en) Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
CA2275890A1 (en) Stable liquid interferon formulations
JP2007508326A (ja) Ｈｃｖ感染のための組み合わせ治療
JP5138699B2 (ja) Ｐｅｇ−インターフェロンアルファ接合体の配合物
JP2004538275A5 (enExample)
EP1066059B1 (en) Formulations for protection of peg-interferon alpha conjugates
CN1712067A (zh) 冷冻干燥的不含白蛋白的重组人第ⅷ凝血因子
CN101351219A (zh) 包含增效比例的干扰素γ和α的稳定的制剂
JP2015535238A (ja) ペグインターフェロンα−２ｂの安定な医薬組成物
JP2005511553A (ja) チモシンアルファ１ペプチド／ポリマー複合体
US6455051B1 (en) Ameliorant for hepatitis C therapeutic effect and application thereof
JP5798628B2 (ja) ウシ顆粒球コロニー刺激因子のための製剤およびその変異体
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
JP6179939B2 (ja) 高濃度γグロブリン製剤の粘度低下方法
WO2007013677A1 (ja) インターフェロン作用物質の活性増強剤
JP2006096751A (ja) インターロイキン−１１徐放性医薬組成物
JP2005035913A (ja) プラス鎖ｒｎａを遺伝情報に持つウイルスに対する治療剤
ES8501982A1 (es) Un procedimiento para obtener una composicion farmaceutica liofilizada a base de interferon y un aminoacido estabilizante.